Literature DB >> 7497456

Synergistic induction of apoptosis in breast cancer cells by tamoxifen and calmodulin inhibitors.

O S Frankfurt1, E V Sugarbaker, J A Robb, L Villa.   

Abstract

Breast cancer cells are relatively resistant to the induction of apoptosis (AP) and drug regimens which readily activate apoptotic death, may enhance the antitumor effect. Rapid and intensive induction of apoptosis was observed in estrogen receptor positive and negative breast cancer cell cultures treated with tamoxifen (TMX) combined with the calmodulin antagonists trifluoperazine (TFP) or W7. TMX (1-5 microM) alone or calmodulin antagonists alone did not induce apoptosis. Importantly, intensive apoptosis was also induced by TMX and TFP in the cells obtained from primary human breast carcinomas. Inhibition of the Ca2+ calmodulin signaling pathway is an effective way to activate apoptotic death in epithelial cells. Combination of TMX with non-toxic calmodulin inhibitors may increase the preventive and therapeutic effects of TMX.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7497456     DOI: 10.1016/0304-3835(95)03970-8

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  14 in total

1.  Calmodulin binds HER2 and modulates HER2 signaling.

Authors:  Colin D White; Zhigang Li; David B Sacks
Journal:  Biochim Biophys Acta       Date:  2010-12-24

2.  Fas binding to calmodulin regulates apoptosis in osteoclasts.

Authors:  Xiaojun Wu; Eun-Young Ahn; Margaret A McKenna; Hyeonju Yeo; Jay M McDonald
Journal:  J Biol Chem       Date:  2005-06-17       Impact factor: 5.157

Review 3.  Is the use of some calcium antagonists linked to cancer? Evidence from recent observational studies.

Authors:  M Pahor; C D Furberg
Journal:  Drugs Aging       Date:  1998-08       Impact factor: 3.923

4.  Role of proliferation and apoptosis in net growth rates of human breast cancer cells (MCF-7) treated with oestradiol and/or tamoxifen.

Authors:  P E Budtz
Journal:  Cell Prolif       Date:  1999-10       Impact factor: 6.831

5.  Apoptosis and tumorigenesis in human cholangiocarcinoma cells. Involvement of Fas/APO-1 (CD95) and calmodulin.

Authors:  G Pan; S M Vickers; A Pickens; J O Phillips; W Ying; J A Thompson; G P Siegal; J M McDonald
Journal:  Am J Pathol       Date:  1999-07       Impact factor: 4.307

6.  Allosteric effects of the antipsychotic drug trifluoperazine on the energetics of calcium binding by calmodulin.

Authors:  Michael D Feldkamp; Susan E O'Donnell; Liping Yu; Madeline A Shea
Journal:  Proteins       Date:  2010-08-01

7.  Schizophyllan inhibits the development of mammary and hepatic carcinomas induced by 7,12 dimethylbenz(α)anthracene and decreases cell proliferation: comparison with tamoxifen.

Authors:  Ahmed Mansour; Ayman Daba; Nahed Baddour; Muhammed El-Saadani; Eiman Aleem
Journal:  J Cancer Res Clin Oncol       Date:  2012-05-03       Impact factor: 4.553

8.  Calmodulin antagonist enhances DR5-mediated apoptotic signaling in TRA-8 resistant triple negative breast cancer cells.

Authors:  Romone M Fancy; Harrison Kim; Tiara Napier; Donald J Buchsbaum; Kurt R Zinn; Yuhua Song
Journal:  J Cell Biochem       Date:  2018-04-16       Impact factor: 4.429

9.  Fas expression prevents cholangiocarcinoma tumor growth.

Authors:  A Pickens; G Pan; J M McDonald; S M Vickers
Journal:  J Gastrointest Surg       Date:  1999 Jul-Aug       Impact factor: 3.452

10.  Combinatorial therapy with tamoxifen and trifluoperazine effectively inhibits malignant peripheral nerve sheath tumor growth by targeting complementary signaling cascades.

Authors:  Stephanie N Brosius; Amy N Turk; Stephanie J Byer; Jody Fromm Longo; John C Kappes; Kevin A Roth; Steven L Carroll
Journal:  J Neuropathol Exp Neurol       Date:  2014-11       Impact factor: 3.685

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.